Skip to main content
. 2013 Oct 18;62(11):3775–3784. doi: 10.2337/db13-0669

FIG. 1.

FIG. 1.

In vivo β-cell expression of IL-2 after dsAAV8mIP-IL2 injection. A: IL-2 levels in supernatants from islets isolated from NOD.scid mice treated with dsAAV8mIP-IL2 or left untreated. **P < 0.01, ***P < 0.001, one-way ANOVA ± SEM. B: Temporal measurement of serum IL-2 from 10–12-week-old NOD female mice (n = 5) treated with dsAAV8mIP-IL2, dsAAV8mIP-EGFP, or left untreated. ***P < 0.001, two-way ANOVA ± SEM. C: Serum IL-2 levels in NOD mice (n = 5) treated with STZ alone, STZ plus AAV8mIP-IL2 (2.5 × 1010 VPs) 72 h later, or AAV8mIP-IL2 (2.5 × 1010 VPs) alone at day 10 post–STZ injection. ***P < 0.001, two-way ANOVA ± SEM. D: Frequency of immune effector cells in peripheral blood of NOD mice left untreated or treated with dsAAV8mIP-IL2 7, 14, and 21 days later. STZ, streptozotocin.